SUBSCRIBE Blog with us: BLOGbiotech

GEN News Highlights

• Email
• Print
• Share
• More GEN News Highlights

Jul 31 2009, 10:58 AM EST

Lonza Launches Fixed-Price Service for Preclinical Manufacturing

GEN News Highlights

Lonza is offering a fixed-price manufacturing service for generating preclinical quantities (up to 1,000 mg) of microbially derived biopharmaceuticals. The company claims its XSpedite Microbial Services™ option can deliver non-GMP proteins and plasmid DNA in 10 to 15 weeks (from strain to purified product) and guarantee the delivery of a minimum quantity after initial lab evaluation.

The new service has been designed so clients can cost-effectively accelerate early-stage microbial biopharmaceutical programs without investment in a full GMP process development program. The XSpedite Microbial Services package also provides a solid basis for future cGMP manufacturing process development, Lonza points out.

“Our customers have emphasized the value of rapid process development and supply of quantities of purified non-GMP material for critical preclinical evaluation such as proof-of-concept studies,” comments Diego Schmidhalter, Ph.D., head of Lonza microbial services. “In response, Lonza has created an integrated and streamlined service offering that can now supply high-quality product for all material needs, from concept through toxicology, clinical, and commercial supply.”

The new XSpedite Microbial Services are fully complementary to Lonza’s AggreSolve™ Protein Aggregation Predictor platform for protein molecular modeling and its high-titer XS Microbial Expression Technologies™. Launch of the XSpedite Microbial Services facility comes just a week after the company announced it was combining its exclusive synthesis and biopharmaceutical business sectors into one single division, Lonza Custom Manufacturing.

 

♦♦♦
Past Lonza News
Lonza to Produce Anti-RhD Antibodies for LFB’s Phase III Trials (July 15, 2009)
Medarex Taps Lonza for Biomanufacturing (July 9, 2009)
Lonza to Manufacture Elusys’ Antianthrax mAb (Jun 16 2009)
Teva and Lonza Set Up Biosimilars JV (Jan. 20, 2009)
Lonza Reports Manufacturing Deal with Osiris and Facility Constructions (July 1, 2008)

• Email
• Print
• Share
• More GEN News Highlights

Comment on this News:

Name:
Title:
Comment:
	HELP US FIGHT SPAMMING ROBOTS by answering the following simple question. It will verify you as a legitimate user wishing to post a comment. Thank you for your cooperation.

CAREER CENTER

WEBINARS

PODCASTS

MOST POPULAR